Objective. Nosebleed, also known as epistaxis, is a common problem that occurs at some point in at least 60% of people in the United States. While the great majority of nosebleeds are limited in severity and duration, about 6% of people who experience nosebleeds will seek medical attention. For the purposes of this guideline, we define the target patient with a nosebleed as a patient with bleeding from the nostril, nasal cavity, or nasopharynx that is sufficient to warrant medical advice or care. This includes bleeding that is severe, persistent, and/or recurrent, as well as bleeding that impacts a patient's quality of life. Interventions for nosebleeds range from self-treatment and home remedies to more intensive procedural interventions in medical offices, emergency departments, hospitals, and operating rooms. Epistaxis has been estimated to account for 0.5% of all emergency department visits and up to one-third of all otolaryngologyrelated emergency department encounters. Inpatient hospitalization for aggressive treatment of severe nosebleeds has been reported in 0.2% of patients with nosebleeds.
special groups of patients, patients with hemorrhagic telangiectasia syndrome (HHT) and patients taking medications that inhibit coagulation and/or platelet function, are included in this guideline. This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the working group. It is not intended to be a comprehensive, general guide for managing patients with nosebleed. In this context, the purpose is to define useful actions for clinicians, generalists, and specialists from a variety of disciplines to improve quality of care. Conversely, the statements in this guideline are not intended to limit or restrict care provided by clinicians based upon their experience and assessment of individual patients.
Action Statements. The guideline development group made recommendations for the following key action statements: (1) At the time of initial contact, the clinician should distinguish the nosebleed patient who requires prompt management from the patient who does not. (2) The clinician should treat active bleeding for patients in need of prompt management with firm sustained compression to the lower third of the nose, with or without the assistance of the patient or caregiver, for 5 minutes or longer. (3a) For patients in whom bleeding precludes identification of a bleeding site despite nasal compression, the clinician should treat ongoing active bleeding with nasal packing. (3b) The clinician should use resorbable packing for patients with a suspected bleeding disorder or for patients who are using anticoagulation or antiplatelet medications. (4) The clinician should educate the patient who undergoes nasal packing about the type of packing placed, timing of and plan for removal of packing (if not resorbable), postprocedure care, and any signs or symptoms that would warrant prompt reassessment. (5) The clinician should document factors that increase the frequency or severity of bleeding for any patient with a nosebleed, including personal or family history of bleeding disorders, use of anticoagulant or antiplatelet medications, or intranasal drug use. (6) The clinician should perform anterior rhinoscopy to identify a source of bleeding after removal of any blood clot (if present) for patients with nosebleeds. (7a) The clinician should perform, or should refer to a clinician who can perform, nasal endoscopy to identify the site of bleeding and guide further management in patients with recurrent nasal bleeding, despite prior treatment with packing or cautery, or with recurrent unilateral nasal bleeding. (8) The clinician should treat patients with an identified site of bleeding with an appropriate intervention, which may include 1 or more of the following: topical vasoconstrictors, nasal cautery, and moisturizing or lubricating agents. (9) When nasal cautery is chosen for treatment, the clinician should anesthetize the bleeding site and restrict application of cautery only to the active or suspected site(s) of bleeding. (10) The clinician should evaluate, or refer to a clinician who can evaluate, candidacy for surgical arterial ligation or endovascular embolization for patients with persistent or recurrent bleeding not controlled by packing or nasal cauterization. (11) In the absence of life-threatening bleeding, the clinician should initiate first-line treatments prior to transfusion, reversal of anticoagulation, or withdrawal of anticoagulation/ antiplatelet medications for patients using these medications. (12) The clinician should assess, or refer to a specialist who can assess, the presence of nasal telangiectasias and/or oral mucosal telangiectasias in patients who have a history of recurrent bilateral nosebleeds or a family history of recurrent nosebleeds to diagnose hereditary hemorrhagic telangiectasia syndrome (HHT). (13) The clinician should educate patients with nosebleeds and their caregivers about preventive measures for nosebleeds, home treatment for nosebleeds, and indications to seek additional medical care. (14) The clinician or designee should document the outcome of intervention within 30 days or document transition of care in patients who had a nosebleed treated with nonresorbable packing, surgery, or arterial ligation/embolization. The policy level for the following recommendation about examination of the nasal cavity and nasopharynx using nasal endoscopy was an option: (7b) The clinician may perform, or may refer to a clinician who can perform, nasal endoscopy to examine the nasal cavity and nasopharynx in patients with epistaxis that is difficult to control or when there is concern for unrecognized pathology contributing to epistaxis.
Keywords epistaxis, nosebleed, nasal packing, nasal cautery, hereditary hemorrhagic telangiectasia (HHT) Received June 10, 2019; accepted November 1, 2019. N osebleed, also known as epistaxis, is a common problem that occurs at some point in at least 60% of people in the United States. 1 While the great majority of nosebleeds are limited in severity and duration, about 6% of people who experience nosebleeds will seek medical attention. 2 For the purposes of this guideline, we define the target patient with a nosebleed as a patient with bleeding from the nostril, nasal cavity, or nasopharynx that is sufficient to warrant medical advice or care. This includes bleeding that is severe, persistent, and/or recurrent, as well as bleeding that impacts a patient's quality of life (QOL).
Interventions for nosebleeds range from self-treatment and home remedies to more intensive procedural interventions in medical offices, emergency departments, hospitals, and operating rooms. Epistaxis has been estimated to account for 0.5% of all emergency department visits and up to one-third of all otolaryngology-related emergency department encounters. 1, 3, 4 Inpatient hospitalization for aggressive treatment of severe nosebleeds has been reported in 6% of patients treated for nosebleeds in emergency departments. 4 The comprehensive management of nosebleeds was recently addressed in 2 sets of publications: a series of guidelines on aspects of epistaxis management in France and an ''audit'' of epistaxis management from the United Kingdom. These 2 sets of publications addressed the initial evaluation of patients with nosebleeds, the use of packing and cautery as initial treatments, the care of nosebleeds in patients who are taking medication that impairs clotting, the use of surgical and endovascular procedures for refractory epistaxis, and the management of nosebleeds in patients with comorbid conditions such as hypertension or hereditary hemorrhagic telangiectasia syndrome (HHT). [5] [6] [7] [8] [9] [10] [11] [12] This multidisciplinary clinical practice guideline has been developed using the guideline development process of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) to create evidence-based recommendations to improve quality and reduce variations in the care of patients with nosebleeds. 13 
Guideline Scope and Purpose
The purpose of this multidisciplinary guideline is to identify quality improvement opportunities in the management of nosebleeds and to create clear and actionable recommendations to implement these opportunities in clinical practice. Expert consensus to fill evidence gaps, when used, is explicitly stated and supported with a detailed evidence profile for transparency. Specific goals of this guideline are to promote best practices, reduce unjustified variations in care of patients with nosebleeds, improve health outcomes, and minimize the potential harms of nosebleeds and/or interventions to treat nosebleeds.
The target patient for the guideline is any individual aged 3 years with a nosebleed or history of nosebleed. Children aged \3 years are excluded, as the guideline development group (GDG) felt that very young, otherwise healthy children rarely required evaluation for nosebleeds. The group also recognized that literature informing treatment of nosebleeds in infants and toddlers was scant. In addition, while bleeding from the nose may occur secondary to a variety of systemic diseases and head and neck disorders, this guideline does not apply to patients who have a diagnosed bleeding disorder, tumors of the nose or nasopharynx, vascular malformations of the head and neck, a history of recent facial trauma, or have undergone nasal and/or sinus surgery in the past 30 days. The management of nosebleeds in such excluded patients centers on treatment of these causative factors, and the recommendations within this guideline may not consistently apply in such cases. Patients with intranasal telangiectasias associated with HHT are not excluded, as the GDG noted opportunity for improved care of these patients with specific recommendations based on studies of HHT patients with epistaxis.
The target audience of this guideline is clinicians who evaluate and treat patients with nosebleed. This includes primary care providers such as family medicine physicians, internists, physician assistants, nurse practitioners, and pediatricians. It also includes specialists such as emergency medicine providers, otolaryngologists, interventional radiologists and neurointerventionalists, hematologists, and cardiologists. A plain-language summary accompanies this clinical practice guideline (CPG) for the use of patients and nonclinicians. The setting for this guideline includes any site of evaluation and treatment for a patient with nosebleed, including ambulatory medical sites, the emergency department, the inpatient hospital, and even outpatient remote encounters with phone calls and telemedicine ( Table 1) . Outcomes to be considered for patients with epistaxis include control of acute bleeding, prevention of recurrent episodes of nasal bleeding, complications of treatment modalities, and accuracy of diagnostic measures. Other considerations are cost, time, and efficiency of diagnostic and treatment measures in patients with nosebleed.
This guideline addresses the diagnosis, treatment, and prevention of nosebleed. It will focus on nosebleeds that commonly present to clinicians with phone calls, office visits, and emergency room encounters. This guideline discusses first-line treatments such as nasal compression, application of vasoconstrictors, and nasal packing. It also addresses more complex epistaxis management, which includes the use of endoscopic arterial ligation and interventional radiology procedures. Management options for 2 special groups of patients, patients with HHT and patients taking medications that inhibit coagulation and/or platelet function, are included in this guideline.
This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the working group. It is not intended to be a comprehensive, general guide for managing patients with nosebleed. In this context, the purpose is to define useful actions for clinicians, generalists, and specialists from a variety of disciplines, to improve quality of care. Conversely, the statements in this guideline are not intended to limit or restrict care provided by clinicians based upon their experience and assessment of individual patients.
Health Care Burden Epidemiology
As noted previously, nearly 60% of the population experience a nosebleed at least once. One-tenth of these patients eventually seek medical advice/intervention and 0.16% will need hospitalization. 14 Many people with nosebleed experience recurrent minor bleeding episodes and may not present for medical attention and instead may use home treatments or simply observe without need for intervention. One survey has shown that nearly one-third of households have 1 household members who experience these minor recurrent nosebleeds. 15 A recent study based on data from the Nationwide Emergency Department Sample (NEDS) from 2009 to 2011 identified 1.2 million emergency department visits for epistaxis in the United States, thus comprising 0.32% of all emergency department encounters. 16 The mean age of patients treated for epistaxis in the emergency department was 53.4 years, and 52.7% were male. In the audit of epistaxis cases managed in the United Kingdom during November 2016, 13.9% of patients treated for epistaxis presented again for treatment within 30 days. 17 These investigators also found a 30-day all-cause mortality rate of 3.4% in these patients.
Nosebleeds seem to affect the population in a bimodal age distribution, with more nosebleeds seen in children and the elderly. 18 A review of the National Hospital Ambulatory Medical Care Survey from 1992 to 2001 demonstrated this bimodal age distribution of patients presenting to emergency departments for treatment of epistaxis, with peak frequency of bleeding in children \10 years of age and in adults between ages 70 and 79 years. 4 A review of Medicare claims data showed an increase in emergency department visits for epistaxis with advanced age, with patients aged 66 to 75 years 1.36 times more likely, patients aged 76 to 85 years 2.37 times more likely, and patients aged .85 years 3.24 times more likely to present to the emergency room than patients \65 years old. 1 Although some studies report a higher incidence of nosebleeds in male patients, 4, 19 other studies have not demonstrated any sex preponderance. 20 Nosebleeds are very common in childhood, with 3 out of 4 children experiencing at least 1 episode of epistaxis according to 1 recent report. 5 Nosebleeds in otherwise healthy children most often are limited bleeds from the anterior nasal septum and can be caused or aggravated by digital trauma, crusting from nasal inflammation, or nasal foreign bodies. Persistent or recurrent nasal bleeding in adolescent males, particularly unilateral nosebleed in the presence of nasal obstruction, could suggest the diagnosis of juvenile nasopharyngeal angiofibroma, an uncommon histologically benign but locally invasive vascular tumor. 21 A recent study of emergency department databases in 4 states showed that children who presented with epistaxis had a mean age of 7.5 years and 57.4% were male. 22 Procedures to control epistaxis were required in 6.9% of these children, with 93.5% of these procedures coded as simple anterior epistaxis control (limited cautery and/or packing). 22 About 5% to 10% of nosebleeds are from posterior sites on the lateral nasal wall or nasal septum not visible by anterior rhinoscopy, known as posterior epistaxis. Posterior epistaxis is more common in older patients and often more difficult to control. 2 One series demonstrated that posterior epistaxis accounted for 5% of all nosebleed patients treated in the emergency department or admitted to the hospital. 23 While epistaxis is usually spontaneous without obvious cause, some nosebleeds can be associated with systemic hematologic, hepatic, renal, genetic, or cardiovascular diseases. Forty-five percent of patients hospitalized for epistaxis had systemic illnesses that likely contributed to the nosebleeds. 24 In the study of epistaxis patients using NEDS, 15% of patients were on long-term anticoagulation, 33% had a history of hypertension, and 0.9% had an underlying coagulation disorder. 16 The often-assumed causal relationship between epistaxis and hypertension is not well established. 18 A recent systematic review of the association of 25 These authors noted the prevalence of hypertension in patients with epistaxis has been reported to be between 24% and 64%. An accompanying commentary provides additional information about available studies of the relationship between hypertension and nosebleed. 26 Nosebleeds are also a recognized problem for patients with known inherited bleeding disorders such as von Willebrand disease or hemophilia, 27 as well as for patients with abnormal nasal vasculature such as that seen in HHT syndrome. 28 Nosebleeds are common in patients taking anticoagulants and medications that impair platelet function. New-generation anticoagulants appear to increase the risk of nosebleed, and algorithms for treating these nosebleeds and indications for discontinuing such medications in these patients are being developed. 6, 12, 29 The increasing use of such medications, with observations of associated nosebleeds, was one of the key concerns of the GDG.
Interventions for Nosebleed
Most nosebleeds originate from the nasal septum, although the lateral nasal wall has a rich vascular supply as well ( Figure 1) .
Initial (''first-line'') treatment can include combinations of direct nasal compression, application of topical agents including vasoconstrictors, cautery of the bleeding site with chemicals or electrocautery, or packing with a variety of resorbable and nonresorbable materials. 18, 30, 31 In the aforementioned review of nosebleeds using NEDS, 19.7% of emergency room visits for epistaxis involved treatment with nasal packing. Fifty-two percent of these patients who required packing also had nasal cautery, 41% had anterior packing alone, and 7% had anterior and posterior nasal packing performed. 16 While the use of topical vasoconstriction and anterior nasal packing is accepted and used widely, questions remain about the types of topical agents, the method of packing, the specific packing materials employed, the duration of packing, and the aftercare for patients with nasal packing. Hemostatic aids such as antifibrinolytic agents and hemostatic packing materials provide additional options for control of nasal bleeding.
A small fraction of patients with nosebleeds refractory to initial local measures will require intensive management, usually with either surgical ligation/cautery of feeder arteries or the use of endovascular embolization procedures. 32 Success of surgical ligation and embolization procedures for acute control of nasal bleeding is .90%. A recent report of a care pathway for patients with severe epistaxis at a tertiary care center advocated for early sphenopalatine artery ligation to improve outcomes and reduce costs. 33 A review of the National Inpatient Sample database from 2008 to 2013 found 1813 cases treated with such procedures, with 57.1% undergoing surgical ligation and 42.9% treated with endovascular embolization. Use of interventional radiology procedures increased over the 5 years of review, although surgical ligation appeared to have fewer airway complications, lower hospital charges, and slightly shorter length of hospital stay. This clinical practice guideline will provide recommendations, as evidence allows, to assist with selection of the most appropriate pathways for initial and rescue treatment of nosebleed.
Cost and Variations in Care
While most patients with nosebleeds may not seek medical care, a small percentage will have bleeding requiring presentation to the emergency department with possible admission for additional consultation and control. Sethi et al 16 reported 132 emergency department visits for epistaxis per 100,000 population yearly. In this sample, 95.5% of epistaxis patients were discharged home from the emergency department. The mean charge for these patients was estimated to be $1146.21 per visit, but the cost increased when nasal packing was used ($1473.29 for packed patients vs $1048.22 for patients who were not packed). 16 A study from Canada reviewed costs when initial emergency department epistaxis management failed and found repeat nasal packing could drive the cost up to $4046.74 CAD ($3035 USD based on April 2018 exchange rates). 34 Charges and costs dramatically increase for patients who require inpatient admission for epistaxis management. Goljo et al 35 noted an average length of stay of 2.24 days with a mean cost of $6925 per admission. They also noted that the presence of renal disease increased costs by $1272 per patient, with some of this increase due to hemodialysis that was required for 16.8% of their admitted patients. Costs were also increased in patients with a history of alcohol abuse and/or sinonasal disease. Costs were even higher in patients of Asian/Pacific Islander descent, top income quartile, or with private payer insurance. When actual hospital charges are considered, as opposed to the patient costs previously noted, the numbers are even more striking. Villwock and Goyal 36 compared costs associated with early or delayed intervention for admitted epistaxis patients and studied costs of surgical ligation in the operating room (endoscopic sphenopalatine ligation) vs angiography with embolization. Early intervention appeared to reduce total cost of hospitalization. They also noted a $30,000 increase in charges for those undergoing embolization ($58,967) as compared to surgical ligation ($28,611). 36 Brinjikji et al 37 expressed additional concerns about the cost of tertiary care for nosebleeds, as they documented a trend to more frequent use of embolization, from 2.8% of admitted nosebleed patients in 2003 to 10.7% in 2010.
These cost analyses indicate variations in care of nosebleed patients, not all of which are readily explained. Male sex (OR, 1.14; 95% CI, 1.10-1.17) and the setting of longterm anticoagulation (OR, 1.21; 95% CI, 1.10-1.33) independently increased the likelihood of treatment with nasal packing. Packing also seemed to occur more often in the Midwest (OR, 1.85; 95% CI, 1.24-2.30) and South (OR 1.62; 95% CI, 1.12-1.34) when compared with the West and more frequently occurred in nontrauma hospitals (OR, 1.56; 95% CI, 1.19-2.05). The authors postulated that increased packing rates could indicate reduced availability of otolaryngologic services. 16 Patients admitted on a weekday were more likely to receive early intervention for nosebleed than those admitted on a weekend (OR, 1.86; 95% CI, 1.34-2.58). 36 In addition, admission to an urban hospital more often resulted in embolization or surgical ligation, likely due to increased availability of specialty services, but an increase in the likelihood of embolization specifically was not seen.
Quality of Life
Nosebleeds are troublesome and adversely affect the QOL of patients and their families. The Parental Stress Index Short Form (PSISF) is a validated test of stress with 3 subscales. 38 The stress on parents of pediatric patients with epistaxis was evaluated using the PSISF, which showed that nearly a one-third of the children and 44% of their parents reported high stress scores. 39 Few, if any, studies measure either baseline QOL or QOL changes with treatment in nosebleed patients, aside from several studies of patients with HHT. These studies of adults with epistaxis and HHT have shown severitydependent effects on QOL and impairment on psychosocial QOL measures. 40, 41 Merlo et al 41 40 115 patients were interviewed, and the authors found that frequent episodes of epistaxis and abundant bleeding decreased psychosocial QOL measures. In addition, these patients expressed ''desire to withdraw'' and ''felt different'' compared to others.
Methods

General Methods
In developing this evidence-based clinical practice guideline, the methods outlined in the third edition of the AAO-HNSF Guideline Development Manual were followed explicitly. 13 
Literature Search
An information specialist conducted several literature searches from November 2017 through March 2018, using a validated filter strategy, to identify CPGs, systematic reviews, randomized controlled trials, and related clinical studies.
The following databases were searched for relevant studies: MEDLINE (OvidSP 1946 to February Week 2, 2018), Embase (OvidSP 1974 to February 16, 2018), CINAHL (EBSCO all years to February 19, 2018), and BIOSIS Previews (all years to February 17, 2018) . All searches were conducted on February 17, 2018, except CINAHL, which was searched on February 19, 2018. The databases were searched using both controlled vocabulary words and synonymous free text words for the topic of interest (epistaxis or nosebleed). The search strategies were adjusted for the syntax appropriate for each database/platform. The search was not limited to clinical study design and English language. The full strategy is shown in the Appendix in the online version of the article. Alternatively, the authors may be contacted directly for search strategy details. These search terms were used to capture all evidence on the population, incorporating all relevant treatments and outcomes. In certain instances, targeted searches for lower-level evidence were performed by the GDG members to address gaps from the systematic searches identified in writing the guideline from April 2018 through October 2018.
The English-language search identified 5 CPGs, 30 systematic reviews, 35 randomized controlled trials, and 238 related studies published through March 2018. Clinical practice guidelines were included if they met quality criteria of (a) an explicit scope and purpose, (b) multidisciplinary stakeholder involvement, (c) systematic literature review, (d) explicit system for ranking evidence, and (e) explicit system for linking evidence to recommendations. Systematic reviews were emphasized and included if they met quality criteria of (a) clear objective and methodology, (b) explicit search strategy, and (c) valid data extraction methods. Randomized controlled trials were included if they met quality criteria as follows: (a) trials involved study randomization, (b) trials were described as double-blind, and (c) trials denoted a clear description of withdrawals and dropouts of study participants. Other studies were included if they were deemed pertinent to the epistaxis topic. After removing duplicates, irrelevant references, and non-Englishlanguage articles, we retained 5 clinical practice guidelines, 17 systematic reviews, and 16 randomized controlled trials that met inclusion criteria. An additional 203 related studies were identified that were related to the key action statements. The recommendations in this clinical practice guideline are based on systematic reviews identified by a professional information specialist using an explicit search strategy. Additional background evidence included randomized controlled trials and observational studies, as needed, to supplement the systematic reviews or to fill knowledge gaps when a review was not available.
The AAO-HNSF assembled the GDG representing the medical disciplines of nursing, family medicine, emergency medicine, otolaryngology-head and neck surgery, pediatrics, rhinology, radiology, internal medicine, and hematology. The GDG also included a consumer/patient representative. The GDG had 3 conference calls and 2 in-person meetings, during which they defined the scope and objectives of the guideline, reviewed comments from the expert panel review for each key action statement, identified other quality improvement opportunities, reviewed the literature search results, and drafted/revised the document.
Key action statements were developed using an explicit and transparent a priori protocol for creating actionable statements based on supporting evidence and the associated balance of benefit and harm. Electronic decision support (BRIDGE-Wiz; Yale Center for Medical Informatics, New Haven, Connecticut) software was used to facilitate creating actionable recommendations and evidence profiles. 42 AAO-HNSF staff used the Guideline Implementability Appraisal (GLIA) to appraise adherence to methodologic standards, to improve clarity of recommendations, and to predict potential obstacles to implementation. 43 The GDG received summary appraisals and modified an advanced draft of the guideline based on the appraisal. The final draft of the clinical practice guideline was revised based on comments received during multidisciplinary peer review, open public comment, and journal editorial peer review. A scheduled review process will occur at 5 years from publication or sooner if new compelling evidence warrants earlier consideration.
Classification of Evidence-Based Statements
Guidelines are intended to produce optimal health outcomes for patients, to minimize harm, and to reduce inappropriate variations in clinical care. The evidence-based approach to guideline development requires the evidence supporting a policy be identified, appraised, and summarized and that an explicit link between evidence and statements be defined. Evidence-based statements reflect both the quality of evidence and the balance of benefit and harm that is anticipated when the statement is followed. The definitions for evidence-based statements are listed in Table 2 44 and Table 3 . 45 Guidelines are not intended to supersede professional judgment but rather may be viewed as a relative constraint on individual clinician discretion in a particular clinical circumstance. Less frequent variation in practice is expected for a ''strong recommendation'' than might be expected with a ''recommendation.''''Options'' offer the most opportunity for practice variability. 46 Clinicians should always act and decide in a way that they believe will best serve their patients' interests and needs, regardless of guideline recommendations. They must also operate within their scope of practice and according to their training. Guidelines represent the best judgment of a team of experienced clinicians and methodologists addressing the scientific evidence for a particular topic. 45 Making recommendations about health practices involves value judgments on the desirability of various outcomes associated with management options. Values applied by the guideline panel sought to minimize harm and diminish unnecessary and inappropriate therapy. A major goal of the panel was to be transparent and explicit about how values were applied and to document the process.
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The cost of developing this guideline, including travel expenses of all panel members, was covered in full by the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF). Potential conflicts of interest for all panel members in the past 2 years were disclosed, compiled, and distributed before the first conference call. After review and discussion of these disclosures, 47 the panel concluded that individuals with potential conflicts could remain on the panel if they (1) reminded the panel of potential conflicts before any related discussion, (2) recused themselves from a related discussion if asked by the panel, and (3) agreed not to discuss any aspect of the guideline with industry before publication. Last, panelists were reminded that conflicts of interest extend beyond financial relationships and may include personal and professional experiences, how a participant earns a living, and the participant's previously established ''stake'' in an issue. 48 Conflicts were again delineated at the start of the in-person meetings and at the start of each teleconference meeting, with the same Strong recommendation A strong recommendation means the benefits of the recommended approach clearly exceed the harms (or that the harms clearly exceed the benefits in the case of a strong negative recommendation) and that the quality of the supporting evidence is excellent (grade A or B). a In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.
Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.
Recommendation A recommendation means the benefits exceed the harms (or that the harms exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong (grade B or C). a In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms.
Clinicians should also generally follow a recommendation but should remain alert to new information and sensitive to patient preferences.
Option An option means that either the quality of evidence that exists is suspect (grade D) a or that well-done studies (grade A, B, or C) a show little clear advantage to one approach vs another.
Clinicians should be flexible in their decision making regarding appropriate practice, although they may set bounds on alternatives. Patient preference should have a substantial influencing role.
a Adapted from the American Academy of Pediatrics classification scheme. 45 caveats followed. All conflicts are disclosed at the end of this document.
Guideline Key Action Statements
Each evidence-based statement is organized in a similar fashion: an evidence-based key action statement in bold, followed by the strength of the recommendation in italics.
Each key action statement is followed by the ''action statement profile'' with quality improvement opportunities, aggregate evidence quality, level of confidence in the evidence, benefit-harm assessment, and statement of costs. In addition, there is an explicit statement of any value judgments, the role of patient preferences, clarification of any intentional vagueness by the panel, exclusions to the statement, any differences of opinion, and a repeat statement of the strength of the recommendation. Several paragraphs subsequently discuss the evidence base supporting the statement. An overview of each evidence-based statement in this guideline can be found in Table 4 .
For the purposes of this guideline, shared decision making refers to the exchange of information regarding treatment risks and benefits, as well as the expression of patient preferences and values, which result in mutual responsibility in decisions regarding treatment and care. 49 For an action statement where the evidence base demonstrates clear benefit, clinicians should provide patients with clear and comprehensible information on the benefits to facilitate patient understanding and shared decision making, which in turn leads to better patient adherence and outcomes. 49 For statements where evidence is weaker or benefits are less certain, the practice of shared decision making is extremely useful, wherein the management decision is made by a collaborative effort between the clinician and an informed patient. 49 Factors related to patient preference include (but are not limited to) absolute benefits (numbers needed to treat), potential adverse effects (number needed to harm), cost of drugs or procedures, frequency and duration of treatment, and certain less tangible factors such as religious and/or cultural beliefs or personal levels of desire for intervention. Level of confidence in evidence: Medium, as available evidence only addresses nosebleed patients who actually seek and receive medical intervention Aggregate evidence quality: Grade C, based on observational studies on the effectiveness of interventions Benefits: Prevention of morbidity and in rare cases mortality; increased likelihood of timely treatment; more efficient allocation of resources to patients in greatest need of treatment; reduction of patient and family stress; avoidance of unnecessary interventions in patients who are not actively bleeding Risk, harm, cost: Delayed treatment of patients who may actually need intervention, overtreatment of patients who are not actively bleeding, increased patient anxiety. No costs are associated with this recommendation. Benefit-harm assessment: Preponderance of benefit over harm Value judgments: None Intentional vagueness: The actual appropriate timing for ''prompt'' management is not specified, as it may vary with different clinical situations; assessment of bleeding severity may occur during telephone/electronic communications or during face-to-face patient encounter. Role of patient preferences: None Exclusions: None Policy level: Recommendation Differences of opinion: None STATEMENT 2. NASAL COMPRESSION: The clinician should treat active bleeding for patients in need of prompt management with firm sustained compression to the lower third of the nose, with or without the assistance of the patient or caregiver, for 5 minutes or longer. Recommendation based on observational studies and a preponderance of benefit over harm.
Key Action Statements
Action Statement Profile: 2
Quality improvement opportunity: To promote effective treatment for nosebleed patients (National Quality Strategy Domain: Patient and family engagement, clinical processes/effectiveness) Level of confidence in evidence: Medium Aggregate evidence quality: Grade C, observational studies and control group of 1 randomized controlled trial Benefits: Use of the simplest method to stop nosebleeds, reduce morbidity, protect airway, reduce need for blood products, improve patient satisfaction, allow for further assessment and management Risk, harm, cost: May delay more definitive management if needed; patient discomfort Benefit-harm assessment: Preponderance of benefit over harm Recommendation 7b: Examination of nasal cavity and nasopharynx using nasal endoscopy The clinician may perform, or may refer to a clinician who can perform, nasal endoscopy to examine the nasal cavity and nasopharynx in patients with epistaxis that is difficult to control or when there is concern for unrecognized pathology contributing to epistaxis. Recommendation 11: Management of patients using anticoagulation and antiplatelet medications In the absence of life-threatening bleeding, the clinician should initiate first-line treatments prior to transfusion, reversal of anticoagulation, or withdrawal of anticoagulation/antiplatelet medications for patients using these medications.
Recommendation
12: HHT identification
The clinician should assess, or refer to a specialist who can assess, the presence of nasal telangiectasias and/or oral mucosal telangiectasias in patients who have a history of recurrent bilateral nosebleeds or a family history of recurrent nosebleeds to diagnose hereditary hemorrhagic telangiectasia syndrome (HHT). The clinician may perform, or may refer to a clinician who can perform, nasal endoscopy to examine the nasal cavity and nasopharynx in patients with epistaxis that is difficult to control or when there is concern for unrecognized pathology contributing to epistaxis. Option based on observational studies with a balance of benefits and harms.
Action Statement Profile: 7b
Quality The clinician should treat patients with an identified site of bleeding with an appropriate intervention, which may include 1 or more of the following: topical vasoconstrictors, nasal cautery, and moisturizing or lubricating agents. Recommendation based on randomized controlled trials and a systematic review with a preponderance of benefit over harm.
Action Statement Profile: 8
Quality improvement opportunity: To initiate appropriate treatment interventions when a bleeding site is identified; to reduce risk of recurrent nasal bleeding (National Quality Strategy Domains: Patient safety, prevention and treatment of leading causes of morbidity and mortality) Level of confidence in evidence: Medium Aggregate evidence quality: Grade B, based on randomized controlled trials and a systematic review Benefits: Provide effective treatment, encourage shared decision making, prevent recurrent bleeding, improve management by using effective therapies and avoiding harm associated with unproven or ineffective therapies Risk, harm, cost: Specific adverse effects based on the treatments used-possible injury from cautery, side effects of vasoconstrictors; cost of treatments; some initial treatments may fail; patient discomfort from treatment Benefit-harm assessment: Preponderance of benefit over harm Value judgments: None Intentional vagueness: A preferred treatment option is not specified, since there is little evidence comparing these options. In fact, combinations of several methods are often used. We also do not specify the order of interventions. Moisturizing and lubricating agents would not likely be used for an active bleed, but such agents would be used after bleeding is stopped with cautery and/or vasoconstrictors. Role of patient preferences: Large Exclusions: None Policy level: Recommendation Differences of opinion: None STATEMENT 9. NASAL CAUTERY: When nasal cautery is chosen for treatment, the clinician should anesthetize the bleeding site and restrict application of cautery only to the active or suspected site(s) of bleeding.
Recommendation based on observational studies with a preponderance of benefit over harm.
Action Statement Profile: 9
Quality improvement opportunity: To limit the application of nasal cauterization to the site of bleeding to reduce damage to additional tissue, to reduce complications related to nasal cautery, to improve patient comfort during cautery (National Quality Strategy Domains: Patient safety, prevention and treatment of leading causes of morbidity and mortality) Level of confidence in evidence: Medium Aggregate evidence quality: Grade C, based on observational studies and indirect evidence from randomized controlled trials comparing types of cautery and a systematic review Benefits: Reduce complications, improve control of pain during the procedure, improve patient satisfaction, avoid injury to healthy tissue, avoid scarring Risk, harm, cost: Possible reaction to the anesthetic medication, delay in treatment if anesthetics not readily available, cost of medication, inadequate control of bleeding, need for additional treatment, some severe nosebleeds and posterior bleeding sites may prove difficult to anesthetize Benefit-harm assessment: Preponderance of benefit over harm Value judgments: The GDG was concerned that topical anesthetics are perhaps underused before nasal cautery. The GDG also noted that cautery may be used in a manner not specifically directed to the specific site of bleeding.
Intentional vagueness: Choice of anesthetic agent and the method of delivery (topical vs injected) were not specified. The method of nasal cautery was also not specified. Role of patient preferences: Moderate for the use of an anesthetic; none for limiting the application of cautery to the identified bleeding site Exclusions: None Policy level: Recommendation Differences of opinion: None STATEMENT 10. LIGATION AND/OR EMBOLI-ZATION FOR PERSISTENT NOSEBLEEDS: The clinician should evaluate, or refer to a clinician who can evaluate, candidacy for surgical arterial ligation or endovascular embolization for patients with persistent or recurrent bleeding not controlled by packing or nasal cauterization. Recommendation based on observational and case-controlled studies, with a preponderance of benefit over harm.
Action Statement Profile: 10
Quality improvement opportunity: To promote the appropriate use and awareness of these methods vs other less invasive use of control to allow more timely intervention in patients with severe or uncontrolled epistaxis (National Quality Strategy Domain: Clinical care) Level of confidence in evidence: High
